Cargando…
Impact of frequent cerebrospinal fluid sampling on Aβ levels: systematic approach to elucidate influencing factors
BACKGROUND: Cerebrospinal fluid (CSF) amyloid-beta (Aβ) peptides are predictive biomarkers for Alzheimer’s disease and are proposed as pharmacodynamic markers for amyloid-lowering therapies. However, frequent sampling results in fluctuating CSF Aβ levels that have a tendency to increase compared wit...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4875639/ https://www.ncbi.nlm.nih.gov/pubmed/27206648 http://dx.doi.org/10.1186/s13195-016-0184-z |
_version_ | 1782433127407288320 |
---|---|
author | Van Broeck, Bianca Timmers, Maarten Ramael, Steven Bogert, Jennifer Shaw, Leslie M. Mercken, Marc Slemmon, John Van Nueten, Luc Engelborghs, Sebastiaan Streffer, Johannes Rolf |
author_facet | Van Broeck, Bianca Timmers, Maarten Ramael, Steven Bogert, Jennifer Shaw, Leslie M. Mercken, Marc Slemmon, John Van Nueten, Luc Engelborghs, Sebastiaan Streffer, Johannes Rolf |
author_sort | Van Broeck, Bianca |
collection | PubMed |
description | BACKGROUND: Cerebrospinal fluid (CSF) amyloid-beta (Aβ) peptides are predictive biomarkers for Alzheimer’s disease and are proposed as pharmacodynamic markers for amyloid-lowering therapies. However, frequent sampling results in fluctuating CSF Aβ levels that have a tendency to increase compared with baseline. The impact of sampling frequency, volume, catheterization procedure, and ibuprofen pretreatment on CSF Aβ levels using continuous sampling over 36 h was assessed. METHODS: In this open-label biomarker study, healthy participants (n = 18; either sex, age 55 − 85 years) were randomized into one of three cohorts (n = 6/cohort; high-frequency sampling). In all cohorts except cohort 2 (sampling started 6 h post catheterization), sampling through lumbar catheterization started immediately post catheterization. Cohort 3 received ibuprofen (800 mg) before catheterization. Following interim data review, an additional cohort 4 (n = 6) with an optimized sampling scheme (low-frequency and lower volume) was included. CSF Aβ(1–37), Aβ(1–38), Aβ(1–40), and Aβ(1–42) levels were analyzed. RESULTS: Increases and fluctuations in mean CSF Aβ levels occurred in cohorts 1–3 at times of high-frequency sampling. Some outliers were observed (cohorts 2 and 3) with an extreme pronunciation of this effect. Cohort 4 demonstrated minimal fluctuation of CSF Aβ both on a group and an individual level. Intersubject variability in CSF Aβ profiles over time was observed in all cohorts. CONCLUSIONS: CSF Aβ level fluctuation upon catheterization primarily depends on the sampling frequency and volume, but not on the catheterization procedure or inflammatory reaction. An optimized low-frequency sampling protocol minimizes or eliminates fluctuation of CSF Aβ levels, which will improve the capability of accurately measuring the pharmacodynamic read-out for amyloid-lowering therapies. TRIAL REGISTRATION: ClinicalTrials.gov NCT01436188. Registered 15 September 2011. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13195-016-0184-z) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4875639 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-48756392016-05-22 Impact of frequent cerebrospinal fluid sampling on Aβ levels: systematic approach to elucidate influencing factors Van Broeck, Bianca Timmers, Maarten Ramael, Steven Bogert, Jennifer Shaw, Leslie M. Mercken, Marc Slemmon, John Van Nueten, Luc Engelborghs, Sebastiaan Streffer, Johannes Rolf Alzheimers Res Ther Research BACKGROUND: Cerebrospinal fluid (CSF) amyloid-beta (Aβ) peptides are predictive biomarkers for Alzheimer’s disease and are proposed as pharmacodynamic markers for amyloid-lowering therapies. However, frequent sampling results in fluctuating CSF Aβ levels that have a tendency to increase compared with baseline. The impact of sampling frequency, volume, catheterization procedure, and ibuprofen pretreatment on CSF Aβ levels using continuous sampling over 36 h was assessed. METHODS: In this open-label biomarker study, healthy participants (n = 18; either sex, age 55 − 85 years) were randomized into one of three cohorts (n = 6/cohort; high-frequency sampling). In all cohorts except cohort 2 (sampling started 6 h post catheterization), sampling through lumbar catheterization started immediately post catheterization. Cohort 3 received ibuprofen (800 mg) before catheterization. Following interim data review, an additional cohort 4 (n = 6) with an optimized sampling scheme (low-frequency and lower volume) was included. CSF Aβ(1–37), Aβ(1–38), Aβ(1–40), and Aβ(1–42) levels were analyzed. RESULTS: Increases and fluctuations in mean CSF Aβ levels occurred in cohorts 1–3 at times of high-frequency sampling. Some outliers were observed (cohorts 2 and 3) with an extreme pronunciation of this effect. Cohort 4 demonstrated minimal fluctuation of CSF Aβ both on a group and an individual level. Intersubject variability in CSF Aβ profiles over time was observed in all cohorts. CONCLUSIONS: CSF Aβ level fluctuation upon catheterization primarily depends on the sampling frequency and volume, but not on the catheterization procedure or inflammatory reaction. An optimized low-frequency sampling protocol minimizes or eliminates fluctuation of CSF Aβ levels, which will improve the capability of accurately measuring the pharmacodynamic read-out for amyloid-lowering therapies. TRIAL REGISTRATION: ClinicalTrials.gov NCT01436188. Registered 15 September 2011. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13195-016-0184-z) contains supplementary material, which is available to authorized users. BioMed Central 2016-05-19 /pmc/articles/PMC4875639/ /pubmed/27206648 http://dx.doi.org/10.1186/s13195-016-0184-z Text en © Van Broeck et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Van Broeck, Bianca Timmers, Maarten Ramael, Steven Bogert, Jennifer Shaw, Leslie M. Mercken, Marc Slemmon, John Van Nueten, Luc Engelborghs, Sebastiaan Streffer, Johannes Rolf Impact of frequent cerebrospinal fluid sampling on Aβ levels: systematic approach to elucidate influencing factors |
title | Impact of frequent cerebrospinal fluid sampling on Aβ levels: systematic approach to elucidate influencing factors |
title_full | Impact of frequent cerebrospinal fluid sampling on Aβ levels: systematic approach to elucidate influencing factors |
title_fullStr | Impact of frequent cerebrospinal fluid sampling on Aβ levels: systematic approach to elucidate influencing factors |
title_full_unstemmed | Impact of frequent cerebrospinal fluid sampling on Aβ levels: systematic approach to elucidate influencing factors |
title_short | Impact of frequent cerebrospinal fluid sampling on Aβ levels: systematic approach to elucidate influencing factors |
title_sort | impact of frequent cerebrospinal fluid sampling on aβ levels: systematic approach to elucidate influencing factors |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4875639/ https://www.ncbi.nlm.nih.gov/pubmed/27206648 http://dx.doi.org/10.1186/s13195-016-0184-z |
work_keys_str_mv | AT vanbroeckbianca impactoffrequentcerebrospinalfluidsamplingonablevelssystematicapproachtoelucidateinfluencingfactors AT timmersmaarten impactoffrequentcerebrospinalfluidsamplingonablevelssystematicapproachtoelucidateinfluencingfactors AT ramaelsteven impactoffrequentcerebrospinalfluidsamplingonablevelssystematicapproachtoelucidateinfluencingfactors AT bogertjennifer impactoffrequentcerebrospinalfluidsamplingonablevelssystematicapproachtoelucidateinfluencingfactors AT shawlesliem impactoffrequentcerebrospinalfluidsamplingonablevelssystematicapproachtoelucidateinfluencingfactors AT merckenmarc impactoffrequentcerebrospinalfluidsamplingonablevelssystematicapproachtoelucidateinfluencingfactors AT slemmonjohn impactoffrequentcerebrospinalfluidsamplingonablevelssystematicapproachtoelucidateinfluencingfactors AT vannuetenluc impactoffrequentcerebrospinalfluidsamplingonablevelssystematicapproachtoelucidateinfluencingfactors AT engelborghssebastiaan impactoffrequentcerebrospinalfluidsamplingonablevelssystematicapproachtoelucidateinfluencingfactors AT strefferjohannesrolf impactoffrequentcerebrospinalfluidsamplingonablevelssystematicapproachtoelucidateinfluencingfactors |